Screening Libraries
Cat. | Size | Price | Stock | |
P20507 | 1mg/well * 10 Compounds | Inquiry | In stock | Contact Us |
P20507 | 100uL/well (10mM solution) * 10 Compounds | Inquiry | In stock |
manager@chemfaces.com | |
Tel | (0086)-27-8423-7683 |
Shelf Life | (0086)-27-84254680 |
Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
Container | 96 Well Format Sample |
Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
Shelf Life | 24 months (2-8 °) |
Intended Use | For research use only. Not for human use. Not sell to patients |
1. The products in the ChemFaces screening libraries are all from plants. |
2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
Catalog No. | Information |
CFN99975 | Ginsenoside Rd Ginsenoside Rd, a minor ginseng saponin, has several pharmacological activities such as immunosuppressive activity, anti-inflammatory activity, immunological adjuvant, anti-cancer activity and wound-healing activity. Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Rd inhibits expression of COX-2 and iNOS mRNA. Rd also inhibits Ca2+ influx. Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively. |
CFN99968 | Ginsenoside Rg2 Ginsenoside Rg2 has therapeutic potential for type 2 diabetic patients, it also may represent a potential neurorestorative treatment strategy for vascular dementia or other ischemic insults, has protective effects against H2O2-induced injury and apoptosis in H9c2 cells. Ginsenoside Rg2 suppresses the hepatic glucose production via AMPK-induced phosphorylation of GSK3β and induction of SHP gene expression, regulates the 5-HT3A receptors that are expressed in Xenopus oocytes, inhibits nicotinic acetylcholine receptor-mediated Na+ influx and channel activity. |
CFN99967 | Ginsenoside Rg1 Ginsenoside Rg1 has antiaging, anti-platelet activation, promotion of wound healing, and neuroprotective effects, it has protective effect against Aβ25-35-induced toxicity in PC12 cells,might be through the insulin-like growth factor-I receptor (IGF-IR) and estrogen receptor (ER)signaling pathways. Ginsenoside Rg1 is a desirable agent for enhancing CD4+ T-cell activity, as well as the correction of Th1-dominant pathological disorders, which by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production. It increased the expression of the vascular endothelial growth factor (VEGF) mRNA and reduced ERK pathway, expression of transforming growth factor beta (TGF-β) mRNA. |
CFN99963 | Pseudoginsenoside F11 Pseudoginsenoside F11, a novel partial PPAR γ agonist, can promote adiponectin oligomerization and secretion in 3T3-L1 adipocytes and inhibit obesity-linked phosphorylation of PPAR γ at Ser-273 by Cdk5. It possesses significant neuroprotective activity, has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice; it also antagonizes the development of analgesia tolerance to morphine and blocks the development of morphine-induced behavioral sensitization via its effect, at least partially, on the glutamatergic system in the mPFC. |
CFN92516 | Chikusetsusaponin IVa Chikusetsusaponin IVa is a novel AMPK activator, can induce insulin secretion from βTC3 cells via GPR40 mediated calcium and PKC pathways, may be developed into a new potential for therapeutic agent used in T2DM patients.Chikusetsusaponin IVa exerts antithrombotic effects, including minor hemorrhagic events. |
CFN99977 | Pseudoginsenoside RT5 Pseudoginsenoside RT5 is a nartural product from Panax ginseng C. A. Mey. |
CFN93281 | Germacrene D The sesquiterpene germacrene D (GD) activates a major type of olfactory receptor neuron on the antennae of the heliothine moths, it can increase attraction and oviposition by the tobacco budworm moth Heliothis virescens. |
CFN92561 | Chikusetsusaponin V methyl ester Standard reference |
CFN92364 | Notoginsenoside R2 Notoginsenoside R2 has neuroprotection against 6-OHDA-induced neurotoxicity, is associated with Notoginsenoside R2-mediated P90RSK and Nrf2 activation through MEK1/2-ERK1/2 pathways. |
CFN90542 | Chikusetsusaponin IV Chikusetsusaponin IV may relieve cutaneous symptoms caused by excessive apoptotic cell death in the skin through the Fas/FasL pathway. |